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A closer view of an oncoprotein-tumor suppressor interaction 
Matthew D Shair 
The cellular response to DNA damage is coordinated by 
the p53 protein. MdmP, an oncoprotein, inhibits p53 and 
promotes ~53 degradation. A recent high-resolution 
structure of the Mdm2-p53 complex may aid the design 
of small molecules to disrupt this interaction, for use in 
investigating the interaction further and for designing 
anticancer drugs. 
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Mutations in thep53 gene have been identified in virtually 
half of all reported cancer cases [l]. As a result, $53 has 
been the subject of extraordinary levels of interest in the 
cancer-biology community. Research efforts have focused 
on ~53 protein functions, including tumor suppression and 
transcriptional activation [Z]. As various stresses, such as 
DNA damage, are imposed on a cell, ~53 orchestrates a 
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The role of p53 in cell-cycle arrest and apoptosis. Upon DNA damage, 
p53 is stabilized, resulting in either cell-cycle arrest and subsequent 
DNA repair, or apoptosis. Shown at the bottom of the figure are 
several of the genes expressed following p53 stabilization and 
transcriptional activation. 
repair, or programmed cell death (apoptosis; Figure 1). In 
normal cells, rapid degradation suppresses ~53 levels. 
Recent reports by Haupt et al. [3] and Kubbutat et al. [4] 
have strongly implicated the proto-oncogene Mdm2 as 
being responsible for initiating the expedient proteolysis of 
~53, thereby heightening the importance of MdmZ in ~53 
regulation (as discussed in more detail below). When DNA 
damage is sensed, degradation of p53 is inhibited and the 
cellular levels of ~53 rapidly elevate. As a transcription 
factor, p.53 is able to cause a halt in cell-cycle progression, 
primarily at the Gl stage, by upregulation of certain gene 
products including p21c1p1~yAF1, which has been identi- 
fied as a potent inhibitor of several cyclin-Cdk complexes 
[5]. The mechanism by which ~53 is able to initiate apop- 
tosis is less clear, however. The bax gene, which has been 
shown to be transcriptionally activated by ~53, may play an 
important role in this response by antagonizing the effects 
of the anti-apoptotic gene bcL? [6]. This minireview will 
summarize recent developments in understanding the mol- 
ecular basis of the regulatory control exerted upon the ~53 
tumor suppressor protein by Mdm2. In addition, the 
potential for disruption of the p53-MdmZ interface by 
small molecules and the use of these molecules for study- 
ing and controlling ~53 function is discussed. 
As well as mutations in thep53 gene that alter the function 
of the ~53 protein directly, p.53 can be altered by changes 
in Mdm2. The Mdm2 protein has been shown to bind to 
~53 and disrupt transcriptional activation by associating 
with the transactivation domain of ~53 [7]. In fact, Mdm2 
overexpression has been implicated in the etiology of one 
third of soft tissue sarcomas [8], presumably as a result of 
sequestration of wild-type ~53 and inactivation of its tumor 
suppression activity. Interestingly, in these sarcomas, mdm2 
overexpression has become an alternative to ~53 mutation. 
Mdm2 is a 490 amino-acid protein that contains a highly 
conserved central acidic region, three putative zinc finger 
motifs and an amino-terminal 100 amino-acid region shown 
to be necessary for ~53 binding (Figure 2). Mutational 
studies of ~53 have shown that Mdm2 binds to and inacti- 
vates the transactivation domain of ~53, which interacts 
with subunits of the general transcription factor TFIID 
(the TAFSl-TAF80 complex; Figure 3) thereby interfer- 
ing with the transcriptional activation machinery of p.53 [9]. 
Mdm2 transcription itself is stimulated by ~53, suggesting 
that there is a negative-feedback loop between p.53 and 
Mdm2. The relevance of this molecular antagonism was 
substantiated by studies in which mice with a targeted 
ma%2 deletion were found to die early during embryonic 
development. The mdmZ ‘knockout’ mice could be rescued 
from embryonic lethality by the simultaneous deletion of 
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~53, however [lO,ll]. These experiments have implicated 
Mdm2 as a negative regulator of the growth-suppressing 
activity of ~53 during early development. 
Mdm2 is involved in ~53 regulation 
As mentioned earlier, recent studies reported by Haupt et 
al. [3] and Kubbutat etal. [4] have further identified a new 
mechanism by which Mdm2 antagonizes ~53 function. A 
strong correlation has been found between the levels of 
both Mdm2 and ~53 proteins. Rapid loss of ~53 coincides 
with maximal MdmZ induction during recovery from DNA 
damage, serving to ensure an effective termination of the 
~53 signal. In fact, an effective time window for ~53 activ- 
ity has been defined as the interval between ~53 activation 
and Mdm2 accumulation. MdmZ appears to regulate ~53 
levels post-transcriptionally, as cells co-transfected with 
Mdm’2 contained normal levels of ~53 messenger RNA. 
Furthermore, Mdm2 transfection promoted rapid degrada- 
tion of ~53 in cells that express ~53 from a constituitive 
promoter [3,4]. This indicates that Mdm’2 overexpression 
induced the destabilization of ~53. Interestingly, ~53 levels 
are maintained if cells are treated with the known protea- 
some inhibitors lactacystin or MG132, suggesting that 
expression of Mdm2 promoted the rapid proteasome- 
dependent degradation of ~53 (Figure 3). 
The molecular basis for MdmZ-dependent regulation of 
~53 has also been explored. Abolition of ~53 binding to 
Figure 3 
Mdm2 by amino-acid substitution on either protein results 
in ~53 levels that are insensitive to Mdm2 overexpression. 
Binding of Mdm2 to ~53 alone, however, is not sufficient 
for degradation of ~53. MdmZ mutants containing only the 
amino-terminal p53-binding region, as well as mutants 
lacking the amino-terminal domain, fail to cause degrada- 
tion of ~53. Hence, full-length MdmZ is required for ~53 
proteolysis. Although the acidic and zinc finger domains of 
MdmZ appear to be necessary for a proteasome-dependent 
response, their roles remain poorly defined and will 
certainly be the focus of future research [12]. 
Structural basis for the Mdm2-p53 interaction 
Recently, a molecular view of the MdmZ-p53 interaction 
was reported, at 2.3A resolution, by Pavletich and co- 
workers [13]. The 12 kDa amino-terminal domain of 
Mdm’2, represented by amino acids 17-125, co-crystallized 
with an 11 amino-acid peptide (residues 17-27) derived 
from ~53 (Figure 4). The highly conserved ~53 peptide had 
been shown, by mutational analysis, to be sufficient for 
Mdm2 binding with an apparent K, of 600nM, compared to 
a K, of 420nM for residues 1-57 of ~53. Residues 17 to 27 
had also been shown to be sufficient for the transactivation 
activity of ~53 [14]. The amino-terminal domain of Mdm2 
consists of two halves that show close structural similarity 
but little sequence homology to one another. A pseudosym- 
metric plane divides the two halves, forming a deep V- 




The effect of Mdm2 on ~53. Mdm2 can block 
the interaction of p53 with the TAF31 -TAWO 
complex, thereby inhibiting transcriptional 
activation. In addition, Mdm2 expression will 
cause degradation of p53 via a proteasome- 
dependent pathway. 
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Figure 4 
A side-on view of the Mdm2-p53 interaction. MdmP is blue and p53 is 
yellow; p53-derived residues critical to the complex are highlighted 
(Trp23, Leu26, and Phel9). Reprinted with permission from 1131. 
lined with several hydrophobic residues and measures 
25 A long, 10 A wide (at the surface) and 10 A deep. Short 
a helices form the floor of the cleft, whereas the sides are 
constructed of long a helices. An 11 amino-acid peptide 
derived from the transactivation domain of ~53 forms an 
amphipathic cx helix of 2.5 turns that inserts into the 
Mdm2 crevice (Figure 5). Phe19, Trp23 and Leu26 of ~53 
protrude into the Mdm2 cleft and Leu22 packs against the 
side wall of MdmZ (Figure 6). As opposed to many of the 
other well-characterized protein-peptide interactions, 
including that of MHC class I [15], in which there is exten- 
sive hydrogen bonding between the protein and peptide, 
there are only two intermolecular hydrogen bonds between 
p.53 and MdmZ. A large proportion of the interactions 
responsible for the tight association of p53 with Mdm2 are 
due to Van der Waals contacts which result in 1498 A2 of 
buried surface area. Mutational studies have shown that p53 
residues Phel9, Trp23 and Leu26, when altered, are the 
most disruptive to the MdmZ-p53 interaction; these 
residues are also essential for transactivation by ~53. The 
mutational studies, corroborated by the structural evidence 
provided by Pavletich and colleagues [13], indicate how 
Mdm2 is able to inhibit interaction of the p53 amphipathic 
helix with the TAF31-TAFBO complex, thereby quelling 
transcriptional activation by ~53. It has been reported that 
the amino-terminal domain of Mdm’2 also targets the 
EZFl-DPl transcription-factor complex, and the interacting 
region of EZFl contains a segment that exhibits high homol- 
ogy with the region of ~53 contacting MdmZ [ 161. Unlike its 
effect on ~53, however, MdmZ stimulates the activation 
potential of the EZFl-DPl complex. The retinoblastoma 
protein (Rb) has also been shown to interact physically and 
functionally with Mdm2, negatively regulating its activity 
[ 171. It will be interesting to watch the emerging story of 
Mdm2 and its impact on growth regulation. 
Synthetic chemistry may play a role in eventually 
modulating ~53 regulation via Mdm2 
The MdmZ-p53 interaction represents an excellent 
opportunity for the use of synthetic chemistry to elucidate 
Figure 5 Figure 6 
A side-on detailed view of the Mdm2-p53 interface. Mdm2 is shown in 
blue and the residues that form contacts with the p53 peptide are light 
blue. The amphipathic p53 CI helix (red) and its sidechains (yellow) are 
also shown. Reprinted with permission from [13]. 
The deep hydrophobic cleft of MdmZ forms an interface with several 
hydrophobic sidechain residues of ~53. Reprinted with permission 
from [131. 
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further the role MdmZ plays in ~53 regulation. In addition, 
it may facilitate the development of novel small-molecule 
therapies for cancer. Using structural information to 
design combinatorial libraries of small molecules, and 
high-throughput yeast-based screening techniques, it may 
be possible to develop small molecules that abrogate the 
MdmZ-p53 association. These small molecules would be 
expected to stabilize p.53 and they may be useful in cases 
where Mdm’2 overexpression is the primary means of ~53 
inactivation. In fact, success has already been registered 
by Lane and coworkers [18] who have identified novel 
Mdm’Z-binding peptides by ‘phage display, and demon- 
strated their activity in &NJ [19]. Clearly, the challenge 
now is to identify small molecules that have equally high 
affinities for MdmZ but that are also cell-permeable. Such 
molecules may be extremely useful as inhibitors of MdmZ 
which could be administered with temporal control to 
probe the role Mdm2 plays in non-transformed cells. 
Interesting questions concerning Mdm2 remain to be 
answered; for example, what functions do the domains 
other than the amino-terminal domain of Mdm2 perform, 
and how do they control the proteasome-dependent pro- 
cessing and regulation of p53? A small molecule that dis- 
rupted the Mdm’Z-p53 interaction might be quite useful 
in studies to answer these questions. As mentioned earlier 
in this review, many soft-tissue sarcomas overexpress 
Mdm2 in the presence of wild-type ~53. These cancers 
may be held in check with small molecules that could 
intercept Mdm2, thereby preventing suppression of ~53. 
Additionally, small-molecule disrupters of MdmZ-p53 
interactions could be used as adjuvant therapy to help 
control and modulate the extent of the p53-dependent 
apoptosis response in conventional chemotherapy. 
Regulation of ~53 by Mdm2 continues to attract research 
efforts at several levels. Each discovery seems to provide an 
equal number of intriguing questions and answers. The 
recent disclosure by two independent laboratories [3,4] that 
an interaction between Mdm2 and ~53 is responsible for 
regulating levels of ~53 in a proteasome-dependent manner 
has enhanced our understanding of ~53 regulation. High- 
resolution crystallographic analysis of the interaction has 
provided a glimpse at the molecular association between an 
oncogene and a tumor suppressor. This snapshot may reveal 
guiding principles for the development of small molecules 
that would be of value both in the laboratory and clinic. 
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